WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
Fax: +47 21 07 81 46
E-mail:
 
Copyright/Disclaimer

New ATC

Overview of new ATC decided at the two previous meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new ATC will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)Deadline for objection to temporary code 1) Implementation in the ATC/DDD index
A02BD11pantoprazole, amoxicillin, clarithromycin and metronidazole01.09.20152016
A05AA04obeticholic acidFinal2016
A08AA62bupropion and naltrexoneFinal2016
A10AE56insulin degludec and liraglutideFinal2016
A10BD20metformin and empagliflozinFinal2016
A10BD21saxagliptin and dapagliflozin01.09.20152016
A10BX14dulaglutide01.09.20152016
A16AB13asfotase alfaFinal2016
A16AB14sebelipase alfaFinal2016
A16AX11sodium benzoate01.09.20152016
B01AC27selexipag01.09.20152016
C01CA27droxidopa01.09.20152016
C09BX02perindopril and bisoprolol01.09.20152016
C09DB08valsartan and lercanidipine01.09.20152016
C09DX04valsartan and sacubitril01.09.20152016
C10BX10rosuvastatin and valsartanFinal2016
C10BX11atorvastatin, amlodipine and perindopril01.09.20152016
D01AC18luliconazoleFinal2016
D01AC19efinaconazoleFinal2016
G03AC10drospirenoneFinal2016
G03CC07conjugated estrogens and bazedoxifene01.09.20152016
J01DD52ceftazidime, combinations01.09.20152016
J01DI54ceftolozane and enzyme inhibitorFinal2016
J01MB08nemonoxacinFinal2016
J01XX11tedizolidFinal2016
J02AC05isavuconazoleFinal2016
J05AR15atazanavir and cobicistatFinal2016
J05AR16lamivudine and raltegravirFinal2016
J05AR17emtricitabine and tenofovir alafenamideFinal2016
J05AR18emtricitabine, tenofovir alafenamide, elvitegravir and cobicistatFinal2016
J05AR19emtricitabine, tenofovir alafenamide and rilpivirine01.09.20152016
J05AX16dasabuvirFinal2016
J05AX65sofosbuvir and ledipasvirFinal2016
J05AX66dasabuvir, ombitasvir, paritaprevir and ritonavir Final2016
J05AX67ombitasvir, paritaprevir and ritonavir Final2016
J06BB19anthrax immunoglobulin01.09.20152016
J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52,58)Final2016
J07BX01smallpox, live attenuatedFinal2016
L01XC17nivolumabFinal2016
L01XC18pembrolizumabFinal2016
L01XC19blinatumomabFinal2016
L01XC21ramucirumab01.09.20152016
L01XC22necitumumab01.09.20152016
L01XE29lenvatinibFinal2016
L01XE31nintedanibFinal2016
L01XE32cediranib01.09.20152016
L01XE33palbociclib01.09.20152016
L01XE34tivozanib01.09.20152016
L01XX48sonidegibFinal2016
L01XX49belinostatFinal2016
L01XX50ixazomib01.09.20152016
L04AA35begelomab01.09.20152016
L04AC12brodalumab01.09.20152016
M04AB05lesinurad01.09.20152016
M05BB08zoledronic acid, calcium and colecalciferol, sequential01.09.20152016
M09AX03atalurenFinal2016
M09AX04drisapersen01.09.20152016
N03AX23brivaracetamFinal2016
N05AX16brexpiprazole01.09.20152016
N05CH03tasimelteonFinal2016
N06BA13armodafinil01.09.20152016
N07XX11pitolisantFinal2016
P03AX06benzyl alcoholFinal2016
R02AA21octenidineFinal2016
R02AX02ibuprofen01.09.20152016
R03AK12salmeterol and budesonide01.09.20152016
R03AL06olodaterol and tiotropiumbromideFinal2016
R03DX08reslizumab01.09.20152016
R07AX30ivacaftor and lumacaftor01.09.20152016
S01XA23sirolimusFinal2016
V03AB37idarucizumab01.09.20152016
1) Final: indicates that the date for objection has expired

Last updated: 2015-04-29